Article Details
Retrieved on: 2025-08-20 20:46:48
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Pilatus Biosciences will evaluate its lead immunotherapy candidate PLT012 in combination with Roche's atezolizumab in a Phase 1 trial.
Article found on: ggba.swiss
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here